IMG_5260‘Join dementia research’ were at Imperial College London’s Health Research Matters event yesterday, raising awareness of research at the College.

The event took place at Hammersmith Hospital, and was attended by healthcare professionals, researchers and patients. The day included tours of the Clinical Research Facility, which provides dedicated space and expertise to enable scientists and physicians to translate their discoveries into health benefit. 115 studies currently take place at Imperial. It was a great insight into some of a participant’s experience of being involved in a study. Part of the tour also included a volunteer wired up to an EEG, which records brain activity, and with them closing their eyes or following a dot on a screen, we were shown how the activity changed.

IMG_5255There was also an opportunity to visit Imperial’s Clinical Imaging Facility, which included seeing a PET scanner and a MRI scanner. With a patient in the MRI scanner, we were shown how activity of the brain (in the images taken) was affected by the participant tapping fingers on their left or right hand.

There were also various talks throughout the day that included ‘Enhancing research through patient and public involvement’ and ‘Innovating how we deliver research’.

Current studies open at Imperial College Healthcare NHS Trust recruiting through ‘Join dementia research’ include:

The AMARANTH drug trial is testing whether an experimental drug (AZD3293 [LY3314814]) is safe and effective in slowing down the progression of Alzheimer’s disease. The investigational drug is designed to reduce the creation of substances that will eventually become amyloid, a brain protein known to build up in excessive amounts in those with, or at risk of, Alzheimer’s disease. The drug may therefore slow down the deterioration of the brain in people with early Alzheimer’s disease. The trial is for people aged between 55-85 with mild Alzheimer’s Disease or Mild Cognitive Impairment, and is being conducted worldwide.

Mild Cognitive Impairment is a condition of recent and mild memory problems, which do not interfere with everyday life. In 10-15% of cases, this can then progress to Alzheimer’s disease. The aim of the Evaluation of microglial activation in Alzheimer’s disease and Mild Cognitive Impairment (GE180) study is to evaluate brain changes (protein build-up in the brain and brain inflammation) seen in some people with Alzheimer’s disease. The researchers hope to learn more about the changes that occur in the brain in people with Alzheimer’s disease and Mild Cognitive Impairment. It is hoped the researchers can use this information to help develop effective preventative treatments in the future.

The ELAD study is evaluating the Liraglutide drug, currently used to treat diabetes, in Alzheimer’s Disease. The drug is used to treat diabetes patients by increasing their production of insulin. Researchers know that insulin is also an important part of the signalling process between nerve cells – and nerve cells are most at risk from the damage caused by dementia.

The Merck MK-8931-019 Drug study aims to test a new medication (MK8931) in the treatment of Mild Cognitive Impairment. This medication acts to reduce the levels of a brain protein called amyloid, which is known to build up in excessive amounts in those with, or at risk of, Alzheimer’s disease.


MRI-V02You can see if you are eligible for any of these studies and various dementia research studies across the nation by logging into your ‘Join dementia research’ account.
Still not registered with ‘Join dementia research’? Why not sign up today?